SCHEMBL5137532

SCHEMBL5137532

CCCCN(Cc1ccc(CO)cc1)Cc1cnc(-c2ccccc2)n1CCCC

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.43
HSD11B1 P28845 2/20 0.40
C5AR1 P21730 1/20 0.36
MAPT P10636 1/20 0.36
AGTR1 P30556 2/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
AGTR2 P50052 1/20 0.35
PGR P06401 1/20 0.35
RORC P51449 1/20 0.35
ACKR3 P25106 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5071535 0.94 TSHR (0.45) TSHRHSD11B1C5AR1AGTR1KDM4E
SCHEMBL1912760 0.92 TSHR (0.48) TSHRHSD11B1C5AR1KDM4EALDH1A1
SCHEMBL5136832 0.91 TSHR (0.42) TSHRHSD11B1C5AR1AGTR1KDM4E
SCHEMBL5072318 0.88 TSHR (0.40) TSHRHSD11B1MAPTKDM4EALDH1A1
SCHEMBL1912927 0.87 TSHR (0.39) TSHRHSD11B1
SCHEMBL5072278 0.86 TSHR (0.51) TSHRHSD11B1C5AR1KDM4EALDH1A1
SCHEMBL5075074 0.86 TSHR (0.46) TSHRHSD11B1
SCHEMBL5135175 0.85 AGTR1 (0.43) MAPTAGTR1KDM4EALDH1A1AGTR2
SCHEMBL5072355 0.85 HSD11B1 (0.45) TSHRHSD11B1C5AR1
SCHEMBL5072498 0.85 TSHR (0.45) TSHRHSD11B1C5AR1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed